Log in

Fulgent Genetics Stock Forecast, Price & News

+2.67 (+8.42 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $34.39
50-Day Range
MA: $35.05
52-Week Range
Now: $34.39
Volume771,091 shs
Average Volume527,827 shs
Market Capitalization$760.53 million
P/E Ratio286.61
Dividend YieldN/A
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Read More
Fulgent Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:FLGT



Sales & Book Value

Annual Sales$32.53 million
Cash Flow$0.17 per share
Book Value$4.42 per share


Net Income$-410,000.00


Market Cap$760.53 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
+2.67 (+8.42 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

How has Fulgent Genetics' stock been impacted by Coronavirus?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLGT shares have increased by 241.8% and is now trading at $34.39.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Fulgent Genetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fulgent Genetics

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Fulgent Genetics

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics Inc (NASDAQ:FLGT) announced its quarterly earnings data on Tuesday, August, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.16. The firm had revenue of $17.27 million for the quarter, compared to the consensus estimate of $14.52 million. Fulgent Genetics had a net margin of 5.78% and a return on equity of 5.05%.
View Fulgent Genetics' earnings history

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics issued an update on its FY 2020 After-Hours earnings guidance on Monday, August, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $135-135 million, compared to the consensus revenue estimate of $121.56 million.

What price target have analysts set for FLGT?

6 brokerages have issued 12 month target prices for Fulgent Genetics' stock. Their forecasts range from $11.00 to $75.00. On average, they expect Fulgent Genetics' share price to reach $33.72 in the next year. This suggests that the stock has a possible downside of 2.0%.
View analysts' price targets for Fulgent Genetics

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,180,000 shares, an increase of 27.3% from the August 15th total of 926,900 shares. Based on an average daily volume of 802,300 shares, the days-to-cover ratio is presently 1.5 days. Currently, 10.6% of the shares of the company are sold short.
View Fulgent Genetics' Short Interest

Who are some of Fulgent Genetics' key competitors?

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), Crispr Therapeutics (CRSP), Inseego (INSG), Marvell Technology Group (MRVL), NeoGenomics (NEO), Square (SQ), InVitae (NVTA), Teladoc Health (TDOC), JD.Com (JD) and Docusign (DOCU).

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
  • Mr. Paul Kim, Chief Financial Officer (Age 52)
  • Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Raymond James Trust N.A. (3.63%), Russell Investments Group Ltd. (2.19%), Old West Investment Management LLC (1.33%), Bank of Montreal Can (1.00%), Essex Investment Management Co. LLC (0.76%) and Cadence Capital Management LLC (0.35%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Ming Hsieh and Paul Kim.
View institutional ownership trends for Fulgent Genetics

Which major investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, Cadence Capital Management LLC, Bank of Montreal Can, Old West Investment Management LLC, Mutual Advisors LLC, ClariVest Asset Management LLC, Two Sigma Advisers LP, and Cornerstone Investment Partners LLC. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics

Which major investors are buying Fulgent Genetics stock?

FLGT stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Trust N.A., Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, California Public Employees Retirement System, and Virtu Financial LLC.
View insider buying and selling activity for Fulgent Genetics

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $34.39.

How big of a company is Fulgent Genetics?

Fulgent Genetics has a market capitalization of $760.53 million and generates $32.53 million in revenue each year. The company earns $-410,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is www.fulgentgenetics.com.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.